Exelixis (EXEL) reported net income of $126.6 million in the third quarter compared to $81.4 million in the third quarter of 2017. The company’s net income over the first nine months of this year amounted to $330.0 million compared to $115.7 million in the same period the prior year.
In the third quarter, Exelixis reported basic EPS and diluted EPS of $0.42 and $0.41, respectively, compared to basic and diluted EPS of $0.28 and $0.26 in the third quarter of 2017. The company’s basic and diluted EPS amounted to $1.11 and $1.05, respectively, in the first nine months of this year. Exelixis reported basic and diluted EPS of $0.39 and $0.37 in the first nine months of 2017. As of September 30, Exelixis’s net cash and cash equivalents, short-term investments, long-term investments, and short-term and long-term restricted cash investments amounted to $750.3 million compared to $457.2 million at the end of December 2017.
Of the 11 analysts tracking Exelixis (EXEL) in November 2018, three of them recommended a “strong buy,” while five analysts recommended a “buy” rating. Two analysts recommended a “hold,” and one analyst recommended a “sell” rating. On October 5, Exelixis had a consensus 12-month target price of $28.56, which represents a ~60.36% return on investment over the next 12 months.
In November 2018, of the 21 analysts tracking Incyte (INCY), ~62% of them recommended “buys,” while among the eight analysts tracking Array Biopharma (ARRY), all of them recommended “buys.” Of the ten analysts tracking Acadia Pharmaceuticals (ACAD), ~80% of them recommended “buys.”
On November 5, Incyte, Array Biopharma, and Acadia Pharmaceuticals (ACAD) had consensus 12-month target prices of $84.0, $25.0, and $33.44, respectively, which would be a 21.79%, ~51.98%, and ~54.39% return on investment over the next 12 months.